Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

Jongh, Felix E. de; Janssen, Harry L.A.; Man, Robert A. de; Hop, Wim C. J.; Schalm, Solko W.; Blankenstein, M. van

doi:10.1016/0016-5085(92)91188-a

Cited by 391 publications

(298 citation statements)

References 31 publications

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…The annual rate of non-HCC-related liver deaths in this report was 3.9% and is similar to rates of 2.4% to 4% reported in other studies. 12,13 In addition, the annual rates for HCC development in our chronic hepatitis patients was 0.9%, and in cirrhosis patients was 2.3%, both of which were similar to HCC incidence rates of 1.5% to 3.8% in Europe 14,15 and rates of 0.7% to 2.2% in Asia. 16,17 Thus, deaths of liver disease complications and HCC development, the two major causes of mortality and morbidity from hepatitis B, appear to be similar among patients from different countries.…”

Section: Discussionsupporting

confidence: 77%

Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States

et al. 2008

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 77%

Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States

et al. 2008

View full text Add to dashboard Cite

“…20,21 In a US study by Weissberg et al, 5-year survival in 130 cirrhotic patients was 55%. 20 Twenty-seven percent of the patients in that study had ascites with a mean serum bilirubin of 1.6 mg/dL and a mean albumin of 3.5 g/dL.…”

Section: Actuarial Analysis Of Hbv Infection After Transplantation Anmentioning

confidence: 99%

A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B

Perrillo¹

2001

Hepatology

402

357

View full text Add to dashboard Cite

Seventy-seven liver transplant candidates were enrolled in a multicenter study in which patients were treated with lamivudine (100 mg daily) without the adjunctive use of hepatitis B immune globulin. Treatment was begun while patients awaited liver transplantation and continued after transplantation. All were hepatitis B surface antigen (HBsAg) positive, and 61% had detectable hepatitis B e antigen (HBeAg) and HBV DNA when treatment was begun. Fortyseven underwent liver transplantation and 30 did not. Median study participation was 38 months (range, 2.7-48.5) in the transplanted patients and 26 months (range, 0.1-37) in the nontransplanted group. Twenty-five of 42 (60%) transplanted patients with 12 or more weeks of posttransplantation follow-up were HBsAg negative at the last study visit. At treatment week 156, 13 of 22 (59%) remained HBsAg negative, and all 9 reinfected patients were HBV-DNA positive before treatment. In the nontransplanted patients, HBeAg was initially detectable in 20 of 27 (74%) but this decreased to 3 of 17 (18%) after 104 weeks of treatment, and significant improvement in biochemical parameters was observed. HBV-DNA polymerase mutants were detected in 15 (21%) and 6 (20%) of the transplanted and nontransplanted patients, respectively. When compared with historical cohorts, lamivudine-treated patients appeared to have improved survival, and transplanted patients had a decrease in the rate of recurrent HBV infection. Lamivudine therapy was partially effective in preventing recurrent HBV infection when given before and after transplantation. Thus, future trials using a combination of HBIg and lamivudine are needed to assess the optimal prophylactic therapy. (HEPATOLOGY 2001;33:424-432.)

show abstract

“…[3][4][5] Disappearance of HBeAg, whether spontaneous or post-antiviral treatment, reduces the risk of hepatic impairment and increases survival. [8][9][10][11] Nevertheless, 10%-30% of the patients can still present high ALT and high levels of HBV-DNA after HBeAg seroconversion and 10%-20% of the inactive carriers may reactivate HBV replication and have exacerbation of hepatitis after years of quiescence. [12][13][14] Most hepatitis flares, after HBeAg seroconversion occur within six months after interferon therapy withdrawal, but can occur later, and even a few years after lamivudine withdrawal.…”

Section: Seroconversion Of Antigen E Of Hepatitis B Virus (Hbeag)mentioning

confidence: 99%

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Ferreira

Tenore

2010

Braz J Infect Dis

View full text Add to dashboard Cite

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotyp

show abstract

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

Cited by 391 publications

References 31 publications

Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States

Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States

A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Contact Info

Product

Resources

About